Iterum Therapeutics plc — Director's Dealing 2018

May 25, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2018-05-24

Reporting Person: Ahrens Brenton Karl (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Shares	$		Ordinary Shares (721408)		Indirect
Series B-1 Preferred Shares	$		Ordinary Shares (275446)		Indirect
Series B-2 Preferred Shares	$		Ordinary Shares (229660)		Indirect

Footnotes

F1: The Series A Preferred Shares are convertible into Ordinary Shares of the Issuer at the option of the holder and have no expiration date. The Series A Preferred Shares will automatically convert into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F2: These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"). Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. The Reporting Person, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. The Reporting Person disclaims Section 16 beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest therein, if any, in such securities by virtue of the limited liability company interests he owns in Canaan X.

F3: The Series B-1 Preferred Shares are convertible into Ordinary Shares of the Issuer at the option of the holder and have no expiration date. The Series B-1 Preferred Shares will automatically convert into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F4: The Series B-2 Preferred Shares are convertible into Ordinary Shares of the Issuer at the option of the holder and have no expiration date. The Series B-2 Preferred Shares will automatically convert into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.